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LETTERS TO THE EDITOR
Phosphate intake and the
CARE study
To the Editor: We read with great interest the Calcium
Acetate Renagel Evaluation (CARE) study report [1].
Although this trial was designed according to the best
standards, patients’ weights were unexpectedly greater
than 11% in the sevelamer group. Phosphate metabolism
not only depends on dialytic clearance, but also on in-
take and absorption [2]. Thus, protein (based on 1.2 g
protein/kg/day), and consequently phosphate (a nearly
constant 1.3% of protein) intakes may have been greater
in the sevelamer group by 10 g protein (e.g., 130 mg phos-
phate per day). It would be of great interest to provide
normalized protein nitrogen appearance (nPNA) in or-
der to rule out this confounding factor.
Similar to phosphate intake, we are left without indi-
cation upon vitamin D doses between groups. Indeed,
combination of higher phosphate intake and vitamin D
might have resulted in a larger phosphate absorption, and
impacted on serum phosphate curve over time (Fig. 1A).
Finally, the short duration of the trial might not have al-
lowed for metabolic equilibrium to occur because, in the
calcium acetate group, serum calcium seems to rise as
soon as four weeks after the start (Fig. 2A), consequently
followed by a rise in CaP product at week six, which could
have counterbalanced the slower control of CaP product
by sevelamer over time.
Hyperphosphatemia is present in more than 50% of
maintenance dialysis patients, and there is a great vari-
ability in its care [3]. There is no need to underline the
difficulty to conduct well-designed studies in this field,
but our remark points out some limitations of the strong
conclusions made by Qunibi et al.
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Reply from the Authors
We thank Dr. Fouque for his thoughtful comments
regarding the CARE study [1]. Indeed, baseline demo-
graphics showed a statistically significant difference in
weight between the two treatment groups, such that the
mean weight was 11% greater in the sevelamer-treated
patients. However, analysis by repeated measures logis-
tic regression showed that the difference in weight be-
tween the two groups had no effect on the primary “goal-
attained” outcomes for serum phosphorus or calcium-
phosphorus product. Moreover, three-day dietary histo-
ries were obtained on all patients at baseline, week four,
and week eight to assess dietary intake of calcium and
phosphorus, and there was not a statistically significant
difference between the two groups at any time point dur-
ing the study. Thus, we conclude that the difference in
baseline weight between the two groups does not ac-
count for our finding that calcium acetate-treatment re-
sulted in better control of serum phosphorus and calcium-
phosphorus product than treatment with sevelamer hy-
drochloride. Unfortunately, we do not have data on nor-
malized protein catabolic rate (nPCR) in our CARE
study patients.
Prestudy use of injectable vitamin D preparations was
similar in the two groups; 65% of the calcium acetate
group versus 60% of the sevelamer group was treated
with vitamin D (P = 0.64). The study was designed such
that the patient’s prestudy dose of vitamin D was contin-
ued and maintained constant throughout the eight-week
treatment period. Vitamin D doses were not modified
in response to hypercalcemia or parathyroid hormone
(PTH) levels.
Finally, the time-averaged serum calcium concentra-
tion was higher by 0.63 mg/dL in the calcium acetate
group, whereas mean serum calcium levels did not change
significantly from baseline values in the sevelamer group.
Thus, the significant difference in calcium-phosphate
product can only be explained by better control of serum
phosphorus in the calcium acetate group. In this regard,
because the magnitude of the change in serum phospho-
rus (Cavg = 1.08 mg/dL over the 8-week study) is larger
than the average change in serum calcium, the attained
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